Japanese / English

Nippon Shinyaku’s R&D Activities

We focus our drug discovery research on strategic fields such as urology and hematology, and on the elucidation of the causes of new diseases. By doing so, we are speedily developing original and unique products.

December 22, 2021
Zogenix Submission of New Drug Application for ZX008 (Fenfluramine Hydrochloride) in Japan
December 10, 2021
Coverage in NHI Drug Price Listing and Launch Date of TADALAFIL Tablets 2.5 mg/5 mg ZA "SIOE"
November 29, 2021
Nippon Shinyaku Implements VILTEPSO Managed Access Program
November 25, 2021
Addition of Viltepso to the List of Injection Drugs That Physicians Providing Health Insurance Treatment Can Administer
November 10, 2021
Nippon Shinyaku enter into an Option Agreement for DYN101 in Japan
September 22, 2021
VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting
September 17, 2021
VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference
August 25, 2021
MHLW approval of Uptravi® for the Treatment of inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or persistent/recurrent CTEPH after surgery
July 01, 2021
VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference
June 25, 2021
Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen) in China
June 21, 2021
Webcast of VILTEPSO® (viltolarsen) injection: Long-Term Data Scheduled for Presentation at the PPMD 2021 Virtual Annual Conference
May 12, 2021
(Media)VILTEPSO injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference
March 23, 2021
(Media)MHLW approval of Vidaza(azacitidine) for the Treatment of Acute Myeloid Leukemia